Fixed combination of a low/moderate-intensity statin + ezetimibe vs high-dose statin

In patients with or at high risk of ASCVD, a fixed combination of a low/moderate-intensity statin with ezetimibe gets more patients to the LDL-C goal and causes fewer adverse effects than high-dose statin therapy. In routine-practice data, cardiovascular events are also fewer on the combination.

Lowering LDL-C is the central task in a patient with atherosclerosis. High-dose statin monotherapy does not get every patient to goal, and adverse events — muscle-related above all — are dose-dependent and drive patients to stop treatment.

The 15–22% range is reported in the meta-analysis discussed here; the “rule of six” is a well-established pharmacological regularity for statins, not a result of this review.

This is the most robust finding of the review — it comes from randomised trials. On the combination, the LDL-C goal of < 1.8 mmol/L was reached 27% more often, and LDL-C itself fell by an additional 0.21 mmol/L compared with a high statin dose.

For every 100 patients reaching LDL-C < 1.8 mmol/L on a high statin dose, 127 reach it on the combination — the “extra” 27% are highlighted in amber.

Conversion mg/dL → mmol/L: cholesterol ÷ 38.67; triglycerides ÷ 88.57. LDL-C: −0.21 mmol/L (95% CI −0.26…−0.15); total cholesterol: −0.69 mmol/L (95% CI −0.71…−0.67).

Muscle complaints and rising liver enzymes are the two main reasons statins get stopped. On the combination both occur roughly half as often: muscle-related adverse events 48% less often and liver-enzyme elevations 49% less often. New cases of diabetes in routine practice were recorded 20% less often.

For every 100 muscle-related adverse events on a high statin dose there are 52 on the combination — that is what “48% less often” means.

Nine of the fifteen studies are observational: they reflect routine clinical care and account for most of the 251,450 patients. Cardiovascular events were fewer on the combination: the composite endpoint 24% less often, cardiovascular death 20% less often, all-cause death 16% less often, and non-fatal stroke 19% less often.

Among patients after myocardial infarction, only 58.9% were still taking a high-intensity statin at 6 months and 41.6% at 2 years. The main reason for stopping is adverse effects. The combination is better tolerated, so the patient is more likely to stay on treatment and hold the LDL-C goal.

Exact adherence figures for the combination itself are not reported in the source — it is described as higher owing to better tolerability.

• If a patient has not reached the LDL-C goal on a low- or moderate-intensity statin, adding ezetimibe achieves more than doubling the statin dose.
• The LDL-C goal of < 1.8 mmol/L is reached 27% more often than on a high statin dose.
• Muscle complaints are 48% less frequent and liver-enzyme elevations 49% less frequent: a direct argument for a patient who cannot tolerate high statin doses.
• New cases of diabetes in routine practice are 20% less frequent.
• A fixed combination is one tablet instead of two: fewer pills and a better chance the patient stays on treatment.
• Limitation: all studies were conducted in Asian countries, and the cardiovascular-event data are predominantly observational.

Source

1. Sydhom P, Al-Quraishi B, El-Shawaf M, et al. The clinical effectiveness and safety of low/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024;24(1):660. PubMed 39567875 · DOI 10.1186/s12872-024-04144-y

All percentages are derived from the published risk ratios (RR) and hazard ratios (HR); exact values with 95% confidence intervals are available in the collapsible “Exact figures” blocks.

The full version of the review with all statistical detail, forest plots and the study-selection flow: extended version.